Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds. During the second quarter, Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) through the purchase of 12,000 shares of the company’s stock. According to a recent disclosure with the SEC, the firm’s investment in the company is approximately $6,300,000 now.
While the company’s returns don’t seem quite compelling, Regeneron Pharmaceuticals, Inc. has what only a few have. In a noteworthy update, the company posted a Phase 2 COURAGE study on September 17, and to much surprise, garetosmab demonstrated exceptional efficacy in treating fibrodysplasia ossificans progressiva.
We already know that Regeneron Pharmaceuticals, Inc. maintains a solid presence in the United States, particularly through the construction of a new manufacturing facility in Rensselaer, along with the deal signed with Fujifilm earlier in April. Given the strong Dupixent growth and a healthy balance sheet, the company is well-positioned for a bright future.
Regeneron Pharmaceuticals, Inc. is a New York-based company specializing in medicines for treating various diseases. Incorporated in 1988, the company offers EYLEA, myopic choroidal neovascularization, neovascular glaucoma, and Dupixent.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
